- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04516135
Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients With Metastatic Gynecologic Cancers
A Randomized Phase II Trial of Palliative Pelvic Radiation Therapy to Improve Health Related Quality of Life in Gynecologic Malignancies
Study Overview
Status
Detailed Description
PRIMARY OBJECTIVE:
I. To determine whether single fraction palliative radiation therapy (SFRT) improves health-related quality of life (HR-QOL) over multi-fraction palliative radiotherapy (MFRT).
SECONDARY OBJECTIVES:
I. To determine whether single fraction palliative radiation therapy (SFRT) improves individual domains of health-related quality of life (HR-QOL) over multi-fraction palliative radiotherapy (MFRT).
II. To determine whether SFRT increases clinically meaningful HR-QOL improvement over MFRT.
III. To determine whether SFRT provides non-inferior symptom burden improvement to MFRT.
IV. To describe radiation related toxicity rates within 21 days and within year for patients receiving SFRT and MFRT.
EXPLORATORY OBJECTIVES:
I. To describe T-cell repertoire of patients receiving SFRT and MFRT. II. To describe vaginal microbiome of patients receiving SFRT and MFRT. III. To describe gut microbiome of patients receiving SFRT and MFRT. IV. To describe financial burden of patients undergoing palliative pelvic radiation with either SFRT or MFRT.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM A: Patients undergo standard of care radiation therapy in the form of 3-dimensional conformal radiation therapy (3D CRT), intensity-modulated radiation therapy (IMRT), or volume modulated arc therapy (VMAT) at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity. Patients with < 30% decrease in the Symptom Inventory Scale (SIS) may receive an additional fraction on day 21 at the physician's discretion.
ARM B: Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for up to 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Lauren Colbert
- Phone Number: 832-652-6033
- Email: lcolbert@mdanderson.org
Study Locations
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Recruiting
- Cooper Hospital University
-
Contact:
- Megan Mezera, M D
- Phone Number: 856-735-6109
- Email: mezera-megan@CooperHealth.edu
-
Principal Investigator:
- Megan Mezera, M D
-
-
Ohio
-
Columbus, Ohio, United States, 43215
- Recruiting
- OhioHealth
-
Contact:
- Megan DeHaan, M D
- Phone Number: 614-566-5560
- Email: megan.dehaan@ohiohealth.com
-
Principal Investigator:
- Megan DeHaan, M D
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- M D Anderson Cancer Center
-
Contact:
- Lauren Colbert
- Phone Number: 832-652-6033
- Email: lcolbert@madanderson.org
-
Principal Investigator:
- Lauren Colbert
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Histologically or cytologically documented gynecologic cancer with prior or current evidence of metastatic disease
- Measurable pelvic disease with any pain and/or bleeding
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 3
- Estimated life expectancy > 3 months at discretion of treating physician
- Female participants of childbearing potential must be willing to use an adequate method of contraception for the course of the study through 120 days after the last dose of study medication
- Patient able to provide properly obtained written informed consent
- Gynecologic Section Radiation Oncology Quality Assurance (QA) for eligibility for single fraction radiation treatment
Exclusion Criteria:
- Prior pelvic radiation therapy that would make treatment unsafe at the discretion of the treating physician
- Systemic therapy concurrently or within 21 days of first dose of radiation
- Concurrent participation in another interventional radiation therapy trial concurrently or within 30 days of study consent. Note: Patients who are participating in systemic clinical trials and non-interventional clinical trials (e.g., QOL, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation
- Known second malignancy that requires active treatment (at the discretion of the primary investigator)
- Documented psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial
- Pregnant or breastfeeding at any point starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm A (radiation therapy)
Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion for 1 fraction in the absence of disease progression or unacceptable toxicity.
Patients with < 30% decrease in the SIS may receive an additional fraction on day 21 at the physician's discretion.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo IMRT
Other Names:
Undergo 3D CRT
Other Names:
Undergo VMAT
Other Names:
|
Active Comparator: Arm B (radiation therapy)
Patients undergo standard of care radiation therapy in the form of 3D CRT, IMRT, or VMAT at the physician's discretion over 2 weeks for 10 fractions in the absence of disease progression or unacceptable toxicity.
|
Ancillary studies
Other Names:
Ancillary studies
Undergo IMRT
Other Names:
Undergo 3D CRT
Other Names:
Undergo VMAT
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change in index value of EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) score
Time Frame: Baseline up to 21 days post-radiation therapy
|
An index value will be calculated for each participant according to page 13 of the user guide.
Scores will be summarized using descriptive statistics.
Will use a 2-sample t-test to compare the change scores between the single fraction palliative radiation therapy (SFRT) and multi-fraction palliative radiation therapy (MFRT) groups.
|
Baseline up to 21 days post-radiation therapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Absolute change in mobility
Time Frame: Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self.
Improvement within each dimension will be assessed by the absolute change of heath state.
A decrease in the raw score by 1 or more points denotes improvement within the dimension.
|
Baseline up to 21 days post-radiation therapy
|
Absolute change in self-care
Time Frame: Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self.
Improvement within each dimension will be assessed by the absolute change of heath state.
A decrease in the raw score by 1 or more points denotes improvement within the dimension.
|
Baseline up to 21 days post-radiation therapy
|
Absolute change in activity
Time Frame: Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self.
Improvement within each dimension will be assessed by the absolute change of heath state.
A decrease in the raw score by 1 or more points denotes improvement within the dimension.
|
Baseline up to 21 days post-radiation therapy
|
Absolute change in pain
Time Frame: Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self.
Improvement within each dimension will be assessed by the absolute change of heath state.
A decrease in the raw score by 1 or more points denotes improvement within the dimension.
|
Baseline up to 21 days post-radiation therapy
|
Absolute change in anxiety
Time Frame: Baseline up to 21 days post-radiation therapy
|
Each dimension is rated on a scale from 1 to 5 where 1 represents no problem present or patient can care for self and 5 represents extreme problems present or unable to care for self.
Improvement within each dimension will be assessed by the absolute change of heath state.
A decrease in the raw score by 1 or more points denotes improvement within the dimension.
|
Baseline up to 21 days post-radiation therapy
|
>= 6 point increase in EuroQol-Visual Analogue Scale
Time Frame: Baseline up to 21 days post-radiation therapy
|
Will summarize the number of patients with clinical meaningful health-related (HR)-quality of life (QOL) improvement using frequencies and proportions.
The proportion of patients with clinically meaningful HR-QOL improvement will be compared between SFRT and MFRT using a chi-squared test.
|
Baseline up to 21 days post-radiation therapy
|
Decrease in Symptom Inventory (SIS)
Time Frame: At 21 days post-radiation therapy
|
Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions.
The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test.
Will be calculated as the average of the worst pain, least pain, pain on average, pain right now and scores from the vaginal bleeding questions.
The change in SIS score from baseline to 21 days post radiation therapy will be calculated for each patient and evaluated between the SFRT and MFRT groups using a t-test.
|
At 21 days post-radiation therapy
|
Incidence of adverse events
Time Frame: Within 21 days and up to 1 year
|
Assessed per Common Terminology Criteria for Adverse Events version 5.0.
Radiation related toxicity event rates within 21 days and within one year for patients receiving SFRT and MFRT will be summarized using frequencies and proportions.
Proportions between SFRT and MFRT will be compared using a chi-squared or Fisher's exact test.
|
Within 21 days and up to 1 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
T-cell repertoire
Time Frame: Up to 1 year
|
Will describe T-cell clonality, diversity, clonal overlap, productive and nonproductive frequencies using descriptive statistics.
Informal comparisons may be completed to generate hypotheses for future studies.
|
Up to 1 year
|
Vaginal microbiome
Time Frame: Up to 1 year
|
Will use alpha and beta diversity metrics for both 16S and whole-genome sequencing (WGS), including overall diversity, richness and evenness and species-specific microbial dynamics.
Will be summarized using descriptive statistics.
Informal comparisons may be completed to generate hypotheses for future studies.
|
Up to 1 year
|
Gut microbiome
Time Frame: Up to 1 year
|
Will use alpha and beta diversity metrics for both 16S and WGS sequencing, including overall diversity, richness and evenness and species-specific microbial dynamics.
Will be summarized using descriptive statistics.
Informal comparisons may be completed to generate hypotheses for future studies.
|
Up to 1 year
|
Financial burden
Time Frame: Up to 21 days
|
Will be assessed using the Economic Strain and Resilience in Cancer Financial Toxicity Questionnaire.
The scores for each question will be summarized using descriptive statistics.
An overall average score will be calculated by calculating the mean score of the seven questions.
At the end of the questionnaire, the patient is asked to rate their overall financial situation as much better, better, nearly the same, worse, or much worse.
The frequency of each answer to the global question will be tabulated.
|
Up to 21 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lauren Colbert, M.D. Anderson Cancer Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2020-0517 (Other Identifier: M D Anderson Cancer Center)
- NCI-2020-05684 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Malignant Female Reproductive System Neoplasm
-
Jonsson Comprehensive Cancer CenterAstraZenecaActive, not recruitingMetastatic Malignant Female Reproductive System Neoplasm | Platinum-Resistant Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Refractory Malignant Female Reproductive System NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingMalignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System Neoplasm | Metastatic Cervical CancerUnited States
-
National Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Malignant Female Reproductive System Neoplasm | Recurrent Malignant Female Reproductive System NeoplasmUnited States
-
Seoul National University Bundang HospitalUnknownMalignant Female Reproductive System NeoplasmKorea, Republic of
-
Rigshospitalet, DenmarkCompletedMalignant Female Reproductive System Neoplasm | Survivorship | Supportive Care | Follow-up | Psychosocial CircumstancesDenmark
-
National Guard Health AffairsSuspendedMalignant Female Reproductive System NeoplasmSaudi Arabia
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid... and other conditionsUnited States, Puerto Rico
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMalignant Solid Neoplasm | Breast Carcinoma | Digestive System Neoplasm | Skin Carcinoma | Malignant Female Reproductive System Neoplasm | Metastatic Malignant Neoplasm of Unknown Primary | Malignant Head and Neck Neoplasm | Malignant Brain Neoplasm | Malignant Central Nervous System Neoplasm | Malignant... and other conditionsUnited States
-
M.D. Anderson Cancer CenterCompletedMalignant Female Reproductive System NeoplasmUnited States
-
Northwestern UniversityCompletedMalignant Female Reproductive System NeoplasmUnited States
Clinical Trials on Quality-of-Life Assessment
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol Specific | Malignant NeoplasmUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)RecruitingChildhood Malignant NeoplasmUnited States, Canada, Puerto Rico, Australia, New Zealand
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedOvarian Clear Cell Cystadenocarcinoma | Ovarian Endometrioid Adenocarcinoma | Ovarian Seromucinous Carcinoma | Ovarian Serous Cystadenocarcinoma | Stage IV Ovarian Germ Cell Tumor | Ovarian Sarcoma | Malignant Ovarian Epithelial Tumor | Ovarian Carcinosarcoma | Ovarian Brenner Tumor | Ovarian Mucinous... and other conditionsUnited States
-
Wake Forest University Health SciencesWithdrawnLung Metastases | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Recurrent Malignant Mesothelioma | Advanced Malignant Mesothelioma
-
City of Hope Medical CenterNational Cancer Institute (NCI)Recruiting
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Neuropathy | COVID-19 InfectionUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingCervical Carcinoma | Endometrial Carcinoma | Vaginal Carcinoma | Malignant Female Reproductive System Neoplasm | Vulvar CarcinomaUnited States
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)Active, not recruitingMetastatic Colorectal Carcinoma | Stage IV Colorectal Cancer AJCC v8 | Stage IVA Colorectal Cancer AJCC v8 | Stage IVB Colorectal Cancer AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Stage III Colorectal Cancer AJCC v8 | Stage IIIA Colorectal Cancer AJCC v8 | Stage IIIB Colorectal Cancer AJCC v8 | Stage IIIC Colorectal Cancer AJCC v8 and other conditionsUnited States